Page last updated: 2024-09-03

pramipexole and Neurodegenerative Diseases

pramipexole has been researched along with Neurodegenerative Diseases in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (20.00)	29.6817
2010's	3 (60.00)	24.3611
2020's	1 (20.00)	2.80

Authors

Authors	Studies
Gencler, OS; Oztekin, MF; Oztekin, N	1
Eijkemans, MJC; Ferguson, TA; Liu, D; Nikolakopoulos, S; van den Berg, LH; van Eijk, RPA	1
Kalaria, DR; Kalia, YN; Merino, V; Patel, P; Patravale, VB	1
Coburn, KL; Doonan, SM; Lauterbach, EC; Mendez, MF; Shillcutt, SD; Victoroff, J	1
Abramova, NA; Bennett, JP; Cassarino, DS; Khan, SM; Painter, TW	1

Reviews

2 review(s) available for pramipexole and Neurodegenerative Diseases

Article	Year
Increasing the efficiency of clinical trials in neurodegenerative disorders using group sequential trial designs. Journal of clinical epidemiology, 2018, Volume: 98 Topics: Amyotrophic Lateral Sclerosis; Central Nervous System Agents; Confidence Intervals; Early Termination of Clinical Trials; Equivalence Trials as Topic; Humans; Medical Futility; Neurodegenerative Diseases; Placebos; Pramipexole; Randomized Controlled Trials as Topic; Research Design; Time Factors	2018
Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data. The Journal of neuropsychiatry and clinical neurosciences, 2010,Winter, Volume: 22, Issue:1 Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Antipsychotic Agents; Benzodiazepines; Benzothiazoles; Brain; Clonazepam; Desipramine; Dibenzothiazepines; Dopamine Agonists; Humans; Lithium Carbonate; Maprotiline; Melatonin; Neurodegenerative Diseases; Neuroprotective Agents; Olanzapine; Parkinson Disease; Pramipexole; Quetiapine Fumarate; Selective Serotonin Reuptake Inhibitors; Valproic Acid	2010

Article

Year

Increasing the efficiency of clinical trials in neurodegenerative disorders using group sequential trial designs.

Journal of clinical epidemiology, 2018, Volume: 98

Topics: Amyotrophic Lateral Sclerosis; Central Nervous System Agents; Confidence Intervals; Early Termination of Clinical Trials; Equivalence Trials as Topic; Humans; Medical Futility; Neurodegenerative Diseases; Placebos; Pramipexole; Randomized Controlled Trials as Topic; Research Design; Time Factors

2018

Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data.

The Journal of neuropsychiatry and clinical neurosciences, 2010,Winter, Volume: 22, Issue:1

Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Antipsychotic Agents; Benzodiazepines; Benzothiazoles; Brain; Clonazepam; Desipramine; Dibenzothiazepines; Dopamine Agonists; Humans; Lithium Carbonate; Maprotiline; Melatonin; Neurodegenerative Diseases; Neuroprotective Agents; Olanzapine; Parkinson Disease; Pramipexole; Quetiapine Fumarate; Selective Serotonin Reuptake Inhibitors; Valproic Acid

2010

Trials

1 trial(s) available for pramipexole and Neurodegenerative Diseases

Article	Year
Comparison of pramipexole versus ropinirole in the treatment of Parkinson's disease. Ideggyogyaszati szemle, 2022, 01-30, Volume: 75, Issue:1-02 Topics: Adult; Aged; Aged, 80 and over; Humans; Indoles; Middle Aged; Neurodegenerative Diseases; Parkinson Disease; Pramipexole	2022

Other Studies

2 other study(ies) available for pramipexole and Neurodegenerative Diseases

Article	Year
Controlled iontophoretic delivery of pramipexole: electrotransport kinetics in vitro and in vivo. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2014, Volume: 88, Issue:1 Topics: Administration, Cutaneous; Animals; Antioxidants; Benzothiazoles; Chromatography, High Pressure Liquid; Ear, External; Electrochemistry; Electroosmosis; Gels; Humans; Iontophoresis; Kinetics; Male; Neurodegenerative Diseases; Parkinson Disease; Pramipexole; Rats; Rats, Wistar; Skin; Sulfites; Swine	2014
Inhibition by R(+) or S(-) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH-SY5Y neuroblastoma. Journal of neuroscience research, 2002, Feb-15, Volume: 67, Issue:4 Topics: 1-Methyl-4-phenylpyridinium; Alzheimer Disease; Amyloid beta-Peptides; Anti-Bacterial Agents; Aristolochic Acids; Benzothiazoles; Bongkrekic Acid; Brain; Caspase Inhibitors; Caspases; Cell Death; Dose-Response Relationship, Drug; Enzyme Inhibitors; Free Radical Scavengers; Humans; Neuroblastoma; Neurodegenerative Diseases; Neurons; Parkinson Disease; Peptide Fragments; Phenanthrenes; Pramipexole; Thiazoles; Tumor Cells, Cultured	2002

Article

Year

Controlled iontophoretic delivery of pramipexole: electrotransport kinetics in vitro and in vivo.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2014, Volume: 88, Issue:1

Topics: Administration, Cutaneous; Animals; Antioxidants; Benzothiazoles; Chromatography, High Pressure Liquid; Ear, External; Electrochemistry; Electroosmosis; Gels; Humans; Iontophoresis; Kinetics; Male; Neurodegenerative Diseases; Parkinson Disease; Pramipexole; Rats; Rats, Wistar; Skin; Sulfites; Swine

2014

Inhibition by R(+) or S(-) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH-SY5Y neuroblastoma.

Journal of neuroscience research, 2002, Feb-15, Volume: 67, Issue:4

Topics: 1-Methyl-4-phenylpyridinium; Alzheimer Disease; Amyloid beta-Peptides; Anti-Bacterial Agents; Aristolochic Acids; Benzothiazoles; Bongkrekic Acid; Brain; Caspase Inhibitors; Caspases; Cell Death; Dose-Response Relationship, Drug; Enzyme Inhibitors; Free Radical Scavengers; Humans; Neuroblastoma; Neurodegenerative Diseases; Neurons; Parkinson Disease; Peptide Fragments; Phenanthrenes; Pramipexole; Thiazoles; Tumor Cells, Cultured

2002